Ross Osborn
Stock Analyst at Cantor Fitzgerald
(2.17)
# 3,047
Out of 5,090 analysts
119
Total ratings
36.7%
Success rate
-1.54%
Average return
Main Sectors:
Stocks Rated by Ross Osborn
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CVRX CVRx, Inc. | Maintains: Overweight | $11 → $13 | $9.05 | +43.65% | 4 | Nov 6, 2025 | |
| PRE Prenetics Global | Maintains: Overweight | $26 → $32 | $13.99 | +128.73% | 8 | Oct 29, 2025 | |
| ORGO Organogenesis Holdings | Maintains: Overweight | $7 → $9 | $4.74 | +89.87% | 4 | Aug 8, 2025 | |
| LMAT LeMaitre Vascular | Maintains: Neutral | $92 → $95 | $84.53 | +12.39% | 2 | Aug 6, 2025 | |
| SIBN SI-BONE | Reiterates: Overweight | $25 | $19.68 | +27.03% | 10 | Aug 5, 2025 | |
| MDXG MiMedx Group | Maintains: Overweight | $11 → $12 | $6.93 | +73.16% | 5 | Jul 31, 2025 | |
| BVS Bioventus | Initiates: Overweight | $12 | $7.09 | +69.25% | 1 | Jul 7, 2025 | |
| XGN Exagen | Maintains: Overweight | $8 → $7 | $7.20 | -2.78% | 6 | May 15, 2025 | |
| LUCD Lucid Diagnostics | Reiterates: Overweight | $2 | $1.03 | +94.17% | 6 | May 15, 2025 | |
| NPCE NeuroPace | Reiterates: Overweight | $17 | $16.40 | +3.66% | 7 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $12 → $9 | $3.64 | +147.25% | 11 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $46 | $21.69 | +112.08% | 6 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $8 | $0.69 | +1,063.64% | 10 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $24 | $33.32 | -27.97% | 3 | Mar 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $4 | $2.06 | +94.17% | 4 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $9 | $4.67 | +92.72% | 1 | Jan 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $21 | $3.50 | +500.00% | 10 | Dec 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $16 | $4.89 | +227.20% | 4 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $3.5 | $2.39 | +46.44% | 5 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $2.5 | $0.30 | +734.17% | 3 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $1.16 | - | 7 | Apr 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $8.61 | $0.33 | +2,517.02% | 2 | Aug 18, 2023 |
CVRx, Inc.
Nov 6, 2025
Maintains: Overweight
Price Target: $11 → $13
Current: $9.05
Upside: +43.65%
Prenetics Global
Oct 29, 2025
Maintains: Overweight
Price Target: $26 → $32
Current: $13.99
Upside: +128.73%
Organogenesis Holdings
Aug 8, 2025
Maintains: Overweight
Price Target: $7 → $9
Current: $4.74
Upside: +89.87%
LeMaitre Vascular
Aug 6, 2025
Maintains: Neutral
Price Target: $92 → $95
Current: $84.53
Upside: +12.39%
SI-BONE
Aug 5, 2025
Reiterates: Overweight
Price Target: $25
Current: $19.68
Upside: +27.03%
MiMedx Group
Jul 31, 2025
Maintains: Overweight
Price Target: $11 → $12
Current: $6.93
Upside: +73.16%
Bioventus
Jul 7, 2025
Initiates: Overweight
Price Target: $12
Current: $7.09
Upside: +69.25%
Exagen
May 15, 2025
Maintains: Overweight
Price Target: $8 → $7
Current: $7.20
Upside: -2.78%
Lucid Diagnostics
May 15, 2025
Reiterates: Overweight
Price Target: $2
Current: $1.03
Upside: +94.17%
NeuroPace
May 14, 2025
Reiterates: Overweight
Price Target: $17
Current: $16.40
Upside: +3.66%
Apr 1, 2025
Maintains: Overweight
Price Target: $12 → $9
Current: $3.64
Upside: +147.25%
Mar 26, 2025
Reiterates: Overweight
Price Target: $46
Current: $21.69
Upside: +112.08%
Mar 7, 2025
Reiterates: Overweight
Price Target: $8
Current: $0.69
Upside: +1,063.64%
Mar 5, 2025
Reiterates: Overweight
Price Target: $24
Current: $33.32
Upside: -27.97%
Feb 21, 2025
Reiterates: Overweight
Price Target: $4
Current: $2.06
Upside: +94.17%
Jan 7, 2025
Initiates: Overweight
Price Target: $9
Current: $4.67
Upside: +92.72%
Dec 24, 2024
Reiterates: Overweight
Price Target: $21
Current: $3.50
Upside: +500.00%
Nov 5, 2024
Reiterates: Overweight
Price Target: $16
Current: $4.89
Upside: +227.20%
Aug 8, 2024
Reiterates: Overweight
Price Target: $3.5
Current: $2.39
Upside: +46.44%
May 16, 2024
Reiterates: Overweight
Price Target: $2.5
Current: $0.30
Upside: +734.17%
Apr 12, 2024
Reiterates: Neutral
Price Target: n/a
Current: $1.16
Upside: -
Aug 18, 2023
Reiterates: Neutral
Price Target: $8.61
Current: $0.33
Upside: +2,517.02%